CATXライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (29 6月 2024 @ 05:00):
Our systems believe the stock currently is overvalued by -1.15% compare to its pairs and should correct downwards.

Stats
本日の出来高	7.95M
平均出来高	749 104
時価総額	672.28M
EPS	$-0.0369 ( Q1 \| 2023-09-30 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-5.86 (Sector) 49.64 (Industry) 37.79
ATR14	$0.0480 (0.49%)

ABT -0.71%

ALUR -23.26%

AORT 3.22%

AVNS 1.63%

BFLY -3.33%

BFLY-WT 4.91%

BIO 0.41%

BIO-B 0.00%

BSX 0.01%

BSX-PA 2.37%

CATX 1.01%

CNMD 2.70%

CRY 1.42%

EW -1.04%

FNA 2.86%

GKOS 0.83%

GMED -0.52%

INSP -1.11%

ITGR 1.10%

MDT 0.10%

NVRO 0.72%

OWLT 6.46%

PEN 2.90%

PHG -1.87%

RBOT -15.78%

SNN 0.12%

SONX 0.00%

STE 1.43%

SYK 0.15%

VAPO -1.87%

ZBH 0.14%

Insider Trading

Date	Person	Action	Amount	type
2024-06-20	Williamson Robert F Iii	Buy	23 000	Stock option (right to buy)
2024-06-20	Morich Frank	Buy	23 000	Stock option (right to buy)
2024-06-20	Woods Lori A	Buy	23 000	Stock option (right to buy)
2024-06-20	Henson Heidi	Buy	23 000	Stock option (right to buy)
2024-06-20	Spoor Johan M.	Buy	500 000	Stock option (right to buy)

INSIDER POWER
99.90
Last 36 transactions
Buy: 62 148 790 \| Sell: 30 000

相関 (AI algo v.1.1b): Overvalued: -1.15% $9.97 paired level. (アルゴリズムは、最も相関の高い株式の変更をリアルタイムで追跡し、即時の更新を提供します)

ボリューム相関

長: 0.35 (neutral)

短: 0.02 (neutral)

Signal:(51.197) Neutral

Perspective Therapeutics, 相関

10 最も正の相関
KLG	0.836
GAQ	0.823
ECCC	0.819
SBXC	0.819

10 最も負の相関
AIU	-0.865
CCG	-0.832
BBAI-WT	-0.828
QBTS	-0.82
GETR	-0.807
RTO	-0.806

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Perspective Therapeutics, 相関 - 通貨/商品

-0.30
( neutral )

-0.14
( neutral )

0.00
( neutral )

-0.35
( neutral )

0.00
( neutral )

0.41
( neutral )

Perspective Therapeutics, 財務諸表

Annual	2022
収益:	$7.10M
総利益:	$1.63M (23.00 %)
EPS:	$-0.100

FY	2022
収益:	$7.10M
総利益:	$1.63M (23.00 %)
EPS:	$-0.100

FY	2022
収益:	$10.80M
総利益:	$4.62M (42.76 %)
EPS:	$-0.0504

Financial Reports:

No articles found.

Perspective Therapeutics, Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Perspective Therapeutics,

Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.